Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.65 |
| ▸ | MMP12 | P39900 | 2/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4827768 | 1.00 | FFAR1 (0.65) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| Methyl 3-Phenylpropanoate SCHEMBL9424369 | 0.95 | TDP1 (0.61) | FFAR1MMP12TDP1HRH3HDAC2 | |
| SCHEMBL6308951 | 0.92 | FFAR1 (0.56) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL12646541 | 0.92 | PTPN1 (0.55) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL14340330 | 0.91 | FFAR1 (0.54) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL13943204 | 0.91 | FFAR1 (0.54) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL6308932 | 0.91 | FFAR1 (0.54) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL14732623 | 0.91 | FFAR1 (0.54) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL14733317 | 0.89 | FFAR1 (0.53) | FFAR1MMP12PTPN1TDP1FFAR4 | |
| SCHEMBL11887471 | 0.89 | FFAR1 (0.53) | FFAR1MMP12PTPN1TDP1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348354-A1 | POLYARYL CARBOXYLIC FULLERENE DERIVATIVE AND USE THEREOF IN ANTI-CORONAVIRUS INFECTION | XIAMEN UNIVERSITY (CN) | 2023-11-02 | — | — | US | claimed |
| CN-114075105-B | Fullerene aryl polycarboxylic acid derivative and application thereof in resisting coronavirus infection | 厦门大学 | 2023-01-10 | — | — | CN | claimed |
| CN-114075105-A | Fullerene aryl polycarboxylic acid derivative and application thereof in resisting coronavirus infection | 厦门大学 | 2022-02-22 | — | — | CN | claimed |
| EP-1438310-B1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TRANSTECH PHARMA INC (US) | 2006-12-20 | — | — | EP | claimed |
| US-6933303-B2 | Heteroaryl-fused nitrogen heterocycles as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2005-08-23 | — | — | US | claimed |
| EP-1438310-A1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TransTech Pharma Inc. (US) | 2004-07-21 | — | — | EP | claimed |
| US-20040014778-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | VTVX HOLDINGS I LLC | 2004-01-22 | — | — | US | claimed |
| WO-2003033496-A1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2003-04-24 | — | — | WO | claimed |
| US-20230348354-A1 | POLYARYL CARBOXYLIC FULLERENE DERIVATIVE AND USE THEREOF IN ANTI-CORONAVIRUS INFECTION | XIAMEN UNIVERSITY (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2023206874-A1 | SACUBITRIL INTERMEDIATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 凯特立斯（深圳）科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| CN-114075105-B | Fullerene aryl polycarboxylic acid derivative and application thereof in resisting coronavirus infection | 厦门大学 | 2023-01-10 | — | — | CN | disclosed |
| CN-114075105-A | Fullerene aryl polycarboxylic acid derivative and application thereof in resisting coronavirus infection | 厦门大学 | 2022-02-22 | — | — | CN | disclosed |
| US-10183909-B2 | Process for preparation of N-Boc biphenyl alaninol | CHIRAL QUEST (SUZHOU) CO., LTD. (CN) | 2019-01-22 | — | — | US | disclosed |
| US-9809537-B2 | Glycosidase inhibitors and uses thereof | ALECTOS THERAPEUTICS INC. (CA) | 2017-11-07 | — | — | US | disclosed |
| EP-1438310-A1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TransTech Pharma Inc. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040014778-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | VTVX HOLDINGS I LLC | 2004-01-22 | — | — | US | disclosed |
| CN-1423627-A | Vitamin D analogues | GALDERMA RES & DEV (FR) | 2003-06-11 | — | — | CN | disclosed |
| WO-2003033496-A1 | BETA-CARBOLIN DERIVATIVES AS PTP-INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| US-5312828-A | Substituted imidazoles having angiotensin II receptor blocking activity | SMITHKLINE BEECHAM CORPORATION A CORP. OF PENNSYLVANIA | 1994-05-17 | — | — | US | disclosed |
| EP-0403158-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014778-A1 | Heteroaryl - fused nitrogen heterocycles as therapeutic agents | PTPRG, PTPRM, PTPRC | FFAR1 1889/4885MMP12 337/4885PTPN1 19/4885 |
| US-10183909-B2 | Process for preparation of N-Boc biphenyl alaninol | RABL6, PF4, SPIN4 | FFAR1 1440/4885MMP12 4744/4885PTPN1 4595/4885 |
| US-20230348354-A1 | POLYARYL CARBOXYLIC FULLERENE DERIVATIVE AND USE THEREOF IN ANTI-CORONAVIRUS INFECTION | SARS1, CRHR1, ACE2 | FFAR1 62/4885MMP12 2782/4885PTPN1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.